<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: An efficient adaptive immunity is critical for a longer survival in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> </plain></SENT>
<SENT sid="1" pm="."><plain>We investigated the prognostic value of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration by CD8(+) T cells expressing the chemokine-receptor-7 (T(ccr7)) and the correlation between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration by T(ccr7) and regulatory CD4(+)FoxP3(+) T cells (T(reg)) in 76 metastatic <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (mCRC) patients enrolled in a phase III trial </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: T(ccr7) and T(reg) cell infiltration in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> samples was quantified by immunohistochemistry </plain></SENT>
<SENT sid="3" pm="."><plain>The correlation among T(ccr7), T(reg) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration, and patients' outcome was evaluated </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: High T(ccr7) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration was predictive of prolonged OS [high vs. low T(ccr7) score: median 38 months (95% CI: 24.5-51.4) vs. 20 months (95% CI: 11.4-28.5); HR = 0.48 (95% CI: 0.24-0.96); P = 0.03] and prolonged progression-free survival [PFS; high vs. low T(ccr7) score: median 12 months (95% CI: 7.7-16.2) vs. 7 months (95% CI: 5.2-8.7); HR = 0.54 (95% CI: 0.28-1.01); P = 0.01] after front-line chemotherapy </plain></SENT>
<SENT sid="5" pm="."><plain>Regression analysis did not show correlation between T(ccr7) and T(reg) infiltration levels </plain></SENT>
<SENT sid="6" pm="."><plain>However, the cluster of patients showing concomitant high infiltration by both T(ccr7) and T(reg) disclosed a favorable outcome [double high vs. double low <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration score: median OS = 35 months (95% CI: 20.8-49.1) vs. 17 months (95% CI: 4.6-29.3); HR = 0.32 (95% CI: 0.12-0.87); P = 0.02 and median PFS = 11 months (95% CI: 9.4-12.5) vs. 5 months (95% CI: 2.2-7.7); HR = 0.43 (95% CI: 0.17-1.06); P = 0.01] </plain></SENT>
<SENT sid="7" pm="."><plain>CONCLUSIONS: High T(ccr7) <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> infiltration score is a favorable prognostic factor for mCRC </plain></SENT>
<SENT sid="8" pm="."><plain>Our findings underline the relevance of microenvironment-related immunologic events for patient outcome </plain></SENT>
</text></document>